HIV microbicides are not currently sold commercially, and many other HIV prevention techniques remain unavailable or unfeasible in developing countries where the disease is most prevalent. The technology transfer effort of developing large scale production methods of CV-N in soy beans helps to address this issue. The ability to produce CV-N in large quantities at low cost affords researchers the potential to develop effective HIV prevention methods worldwide.
 

NCI Scientific Team:
• Barry R. O’Keefe, Ph.D., Deputy Chief, Molecular Targets Laboratory (MTL), CCR, and Chief, Natural Products Branch, Division of Cancer Treatment and Diagnosis (DCTD) 
• Michael R. Boyd, Ph.D., M.D., Chief, Laboratory of Drug Discovery, Research and Development, retired
• James B. McMahon, Ph.D., Chief, MTL, CCR, retired

NCI Technology Transfer Center (TTC):
• Bjarne Gabrielsen, Ph.D., Technology Transfer Manager (TTM), retired
• Mike Currens, Ph.D., Special Assistant to Developmental Therapeutics Program Associate Director, Office of the Director, DCTD, formerly with TTC
• Melissa Maderia, Ph.D., TTM, University of Illinois at Chicago, formerly with TTC 
 

Partners:
• Elíbio Rech, Ph.D., E Genetic Resources department of EMBRAPA 
• Rachel Chikwamba, Ph.D., Council for Scientific and Industrial Research (CSIR Biosciences)